Newsfile Corp
12 Sept 2026, 20:00 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Regeneron's Phase 3 Trial of Fianlimab failed to reach statistical significance for its primary endpoint of improvement in progression-free survival (PFS). — The failure of a Phase 3 clinical trial is a major setback for a pharmaceutical company's pipeline and future revenue potential.
-0.80A class action lawsuit has been filed against Regeneron and its executives alleging they made false or misleading statements regarding the Fianlimab-Libtayo Study. — Securities litigation creates legal uncertainty, potential financial liabilities, and reputational damage to management.
-0.40The lawsuit alleges that Regeneron's preliminary statistical assumptions for the trial were fundamentally flawed and that it failed to achieve clinical differentiation over standard therapies. — Claims of systemic flaws in trial design suggest deeper operational or scientific failures beyond a simple trial miss.
-0.30Which stocks this story touches
Continue reading
5 related stories
Top 1 mover · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
11h ago
